Study summary · research use only
Self-delivery of metal-coordinated mitochondria protonophore uncoupler for O(2)-exhausting enhanced bioreductive therapy
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study combining nanomedicine synthesis with in vivo tumor experiments (species not specified), researchers developed a metal-coordinated mitochondria protonophore uncoupler, Cu-BAQ, self-assembled from copper ion, the uncoupler BAM15, and the bioreductive drug AQ4N, for oxygen-exhausting bioreductive therapy. After intravenous administration, Cu-BAQ was reported to accumulate at the tumor site, exhibited glutathione (GSH)-responsive drug release, and released BAM15 was associated with increased mitochondrial uncoupling and cell respiration. The authors report this led to increased oxygen consumption and local hypoxia that activated AQ4N. In vivo, Cu-BAQ was reported to regulate the tumor hypoxia microenvironment and reduce tumor growth with limited side effects.
Abstract
Mitochondrial uncouplers are capable of maximizing cell respiration to induce local hypoxia, which provides a promising target for bioreductive therapy. In this work, we develop a metal-coordinated mitochondria protonophore uncoupler (designated as Cu-BAQ) for O2-exhausting enhanced bioreductive therapy. In brief, carrier free Cu-BAQ is self-assembled by copper ion (Cu2+), mitochondria protonophore uncoupler (BAM15) and bioreductive drug (AQ4N), which possesses a favorable stability and an improved bioavailability. After intravenous administration, nanosized Cu-BAQ prefers to accumulate at tumor site for effective cellular uptake. Moreover, the Cu2+-coordinated nanomedicine of Cu-BAQ exhibits a glutathione (GSH) responsive drug release behavior and the released BAM15 could promote the mitochondria uncoupling to maximize the cell respiration. As a result, the excessive O2 consumption would induce local hypoxia to activate AQ4N for enhanced bioreductive therapy. In vivo investigations demonstrate that Cu-BAQ is able to regulate tumor hypoxia microenvironment and significantly inhibit tumor growth with a minimized side effect. This GSH-responsive self-delivery nanoplatform provides a new insight for the development of individualized biomedicine for hypoxic tumor precision therapy.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.